 Everolimus
"Everolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.
| Descriptor ID |
D000068338
|
| MeSH Number(s) |
D02.540.505.760.500
|
| Concept/Terms |
Everolimus- Everolimus
- SDZ RAD
- RAD, SDZ
- SDZ-RAD
- 40-O-(2-hydroxyethyl)-rapamycin
|
Below are MeSH descriptors whose meaning is more general than "Everolimus".
Below are MeSH descriptors whose meaning is more specific than "Everolimus".
This graph shows the total number of publications written about "Everolimus" by people in this website by year, and whether "Everolimus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 | | 1999 | 0 | 2 | 2 | | 2000 | 0 | 5 | 5 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 3 | 3 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 4 | 4 | | 2012 | 0 | 4 | 4 | | 2013 | 0 | 6 | 6 | | 2014 | 0 | 4 | 4 | | 2015 | 5 | 1 | 6 | | 2016 | 5 | 1 | 6 | | 2017 | 2 | 2 | 4 | | 2018 | 1 | 0 | 1 | | 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Everolimus" by people in Profiles.
-
Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, Camidge DR, Iwata H, Powell CA. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Aug; 183(1):23-39.
-
Schniedewind B, Meyer EJ, Christians U. Long-Term Performance of Laboratory-Developed Liquid Chromatography-Tandem Mass Spectrometry Tests and a Food and Drug Administration-Approved Immunoassay for the Therapeutic Drug Monitoring of Everolimus. Ther Drug Monit. 2020 06; 42(3):421-426.
-
Place AE, Pikman Y, Stevenson KE, Harris MH, Pauly M, Sulis ML, Hijiya N, Gore L, Cooper TM, Loh ML, Roti G, Neuberg DS, Hunt SK, Orloff-Parry S, Stegmaier K, Sallan SE, Silverman LB. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 07; 65(7):e27062.
-
Flannery PC, DeSisto JA, Amani V, Venkataraman S, Lemma RT, Prince EW, Donson A, Moroze EE, Hoffman L, Levy JMM, Foreman N, Vibhakar R, Green AL. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep. 2018 Feb; 39(2):455-464.
-
Lesche D, Sigurdardottir V, Leichtle AB, Nakas CT, Christians U, Englberger L, Fiedler M, Largiadèr CR, Mohacsi P, Sistonen J. Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement. Metabolomics. 2017 11 25; 14(1):3.
-
Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 2017 Jun 01; 28(6):1339-1345.
-
Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. . 2017 07; 16(7):1389-1400.
-
Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guérin A. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Adv Ther. 2016 06; 33(6):983-97.
-
Musa F, Alard A, David-West G, Curtin JP, Blank SV, Schneider RJ. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2016 07; 15(7):1557-67.
-
Guérin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. Expert Opin Pharmacother. 2016 Jun; 17(9):1189-96.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|